(Q41494492)

1 October 2017

1 reference

title

Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection (English)

1 reference

1 October 2017

1 reference

1 reference

Adkins JC

1

1 reference

1 October 2017

Peters DH

series ordinal

2

1 reference

1 October 2017

Faulds D

series ordinal

3

1 reference

1 October 2017

1 June 1997

1 reference

1 October 2017

1 reference

1 October 2017

53

1 reference

1 October 2017

6

1 reference

1 October 2017

1054-1080

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753060-00009

1 October 2017

0 references

cites work

Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content

1 reference

12 December 2020

Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathy.

1 reference

12 December 2020

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients

1 reference

12 December 2020

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

12 December 2020

Erythema multiforme secondary to dideoxycytidine (ddC)

1 reference

12 December 2020

Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro

1 reference

12 December 2020

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee

1 reference

12 December 2020

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

1 reference

12 December 2020

Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group

1 reference

12 December 2020

The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients

1 reference

12 December 2020

CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine

1 reference

12 December 2020

In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages

1 reference

12 December 2020

Cardiomyopathy Associated with Antiretroviral Therapy in Patients with HIV Infection: A Report of Six Cases

1 reference

12 December 2020

Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme.

1 reference

12 December 2020

The effects of renal impairment on the pharmacokinetics of zalcitabine

1 reference

12 December 2020

The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy

1 reference

12 December 2020

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages

1 reference

12 December 2020

Viral resistance and the selection of antiretroviral combinations

1 reference

12 December 2020

Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine

1 reference

12 December 2020

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

1 reference

12 December 2020

Measuring viral load in the clinical setting.

1 reference

12 December 2020

Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

12 December 2020

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

12 December 2020

The development of resistance of HIV-1 to zalcitabine

1 reference

12 December 2020

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

12 December 2020

Esophageal Ulceration Related to Zalcitabine (ddC)

1 reference

12 December 2020

Improved combined solid-phase extraction-RIA method for quantifying zalcitabine in plasma

1 reference

12 December 2020

Hypersensitivity syndrome associated with zalcitabine therapy

1 reference

12 December 2020

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

12 December 2020

Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

12 December 2020

Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine

1 reference

12 December 2020

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

1 reference

12 December 2020

Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs

1 reference

12 December 2020

Antiretroviral drug interactions

1 reference

12 December 2020

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

1 reference

12 December 2020

Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus

1 reference

12 December 2020

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

12 December 2020

Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection

1 reference

12 December 2020

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

1 reference

12 December 2020

Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group

1 reference

12 December 2020

Occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type 1

1 reference

12 December 2020

Clinical pharmacokinetics of nucleoside antiretroviral agents

1 reference

12 December 2020

Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity

1 reference

12 December 2020

Antiretroviral therapy for infection due to human immunodeficiency virus in children

1 reference

12 December 2020

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

1 reference

12 December 2020

Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.

1 reference

12 December 2020

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

12 December 2020

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group

1 reference

12 December 2020

Mammalian deoxyribonucleoside kinases

1 reference

12 December 2020

1 reference

12 December 2020

Pancreatitis possibly related to 2'-3'-dideoxycytidine

1 reference

12 December 2020

Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control

1 reference

12 December 2020

Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages

1 reference

12 December 2020

Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors

1 reference

12 December 2020

Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine

1 reference

12 December 2020

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

12 December 2020

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis

1 reference

12 December 2020

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

12 December 2020

Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid

1 reference

12 December 2020

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

1 reference

12 December 2020

2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line

1 reference

12 December 2020

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

1 reference

12 December 2020

Zalcitabine and didanosine

1 reference

12 December 2020

Mitochondrial toxicity of antiviral drugs

1 reference

12 December 2020

Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages

1 reference

12 December 2020

Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC).

1 reference

12 December 2020

Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.

1 reference

12 December 2020

Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection

1 reference

12 December 2020

Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.

1 reference

12 December 2020

The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds

1 reference

12 December 2020

Comparative embryonic cytotoxicity of antiretroviral nucleosides

1 reference

12 December 2020

Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation

1 reference

12 December 2020

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases

1 reference

12 December 2020

Surrogate markers in AIDS research. Is there truth in numbers?

1 reference

12 December 2020

Treatment of AIDS with combinations of antiretroviral agents

1 reference

12 December 2020

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

12 December 2020

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party

1 reference

12 December 2020

A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.

1 reference

12 December 2020

Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives

1 reference

12 December 2020

Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus

1 reference

12 December 2020

Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

12 December 2020

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

12 December 2020

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

12 December 2020

Ototoxicity associated with dideoxycytidine

1 reference

12 December 2020

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Importance of surrogate markers in evaluation of antiviral therapy for HIV infection

1 reference

12 December 2020

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

1 reference

12 December 2020

HIV-1, the brain, and combination therapy

1 reference

12 December 2020

Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro

1 reference

12 December 2020

The XI international conference on AIDS. Vancouver 7-12 July 1996. A review of Clinical Science Track B.

1 reference

12 December 2020

Zalcitabine. Clinical pharmacokinetics and efficacy.

1 reference

12 December 2020

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study

1 reference

12 December 2020

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

12 December 2020

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

12 December 2020

Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries

1 reference

12 December 2020

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

1 reference

12 December 2020

Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum

1 reference

12 December 2020

Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children

1 reference

12 December 2020

Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis

1 reference

12 December 2020

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

1 reference

12 December 2020

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

1 reference

12 December 2020

Adverse events from drug therapy for human immunodeficiency virus disease

1 reference

12 December 2020

Combination therapy from a clinician's perspective

1 reference

12 December 2020

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

12 December 2020

Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection

1 reference

12 December 2020

Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides

1 reference

12 December 2020

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.

1 reference

12 December 2020

Failure of antiretroviral therapy: role of viral and cellular factors

1 reference

12 December 2020

Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine

1 reference

12 December 2020

2',3'-Dideoxycytidine induced drug resistance in human cells.

1 reference

12 December 2020

Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.

1 reference

12 December 2020

Triple combinations: present and future.

1 reference

12 December 2020

Pancreatic lesions in HIV-infected patients

1 reference

12 December 2020

Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.

1 reference

12 December 2020

Neuropsychiatric aspects of HIV infection

1 reference

12 December 2020

Primary care of children with HIV infection.

1 reference

12 December 2020

Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1.

1 reference

12 December 2020

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

1 reference

12 December 2020

Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.

1 reference

12 December 2020

A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Nucleoside analogs: similarities and differences

1 reference

12 December 2020

Drug interactions with antiviral drugs

1 reference

12 December 2020

10.2165/00003495-199753060-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

1 October 2017

0 references

1 reference